Clinical trial
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer…
NCT02684006 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT02684006 |
|---|---|
| Title | A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) |
| Official title | A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA(REGISTERED)) VERSUS SUNITINIB (SUTENT(REGISTERED)) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Renal Cell Cancer |
| Intervention type | Drug |
| Interventions | Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib |
| Enrollment | 886 |
| Start date | Mar 23, 2016 |
| Primary completion | Aug 31, 2023 |
| Completion | Jun 26, 2024 |
| First posted | Feb 17, 2016 |
| Last update posted | Jul 30, 2025 |
| Countries | Australia, Austria, Belgium, Canada, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Mexico and 9 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: